A Phase 2 interventional study of MSTT1041A and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 138 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-28.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Asthma by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Asthma · Hoffmann-La Roche.
Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2016, is one of 19 in phase 2, and was the 38th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 41 studies in Asthma by Hoffmann-La Roche is open now. The open studies under Asthma, anywhere →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 517 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 135 across the 35 interventional studies, 309 across the 3 observational. Of the 39 that completed or were terminated, 16 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 41 studies in Asthma by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
Drug: MSTT1041A
Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
Drug: MSTT1041A
Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
Drug: MSTT1041A
Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
Drug: Placebo
MSTT1041A will be administered as subcutaneous injections.
Also known as: RO7187807
Placebo matched with MSTT1041A.
Reduction in Rate of Asthma Exacerbations
Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Adjusted rates for the overall mITT population (all participants that received at least one dose of study drug) were estimated using Poisson regression and adjusted for blood eosinophil level at the first visit, the number of asthma exacerbations requiring systemic corticosteroids in the 12 months prior to study entry, the total daily ICS dose at the first visit, and geographic region, with patient time at risk used as an offset term.
Time frame: Baseline to Week 54
Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
FEV1 measures how much air a person can exhale during the first second of a forced breath. Adjusted means are reported.
Time frame: Baseline to Week 54
Time to First Asthma Exacerbation
Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days.
Time frame: 52 Weeks
Achievement in Improvement in Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S)) Score
The AQLQ measures the functional problems (physical, emotional, social, and occupational) most troublesome to adults (17-70 years) with asthma. There are 32 questions in 4 domains - symptoms, activity limitation, emotional function, and environmental stimuli - scored on a 7 point scale, with 7= no impairment and 1= severely impaired. For this study, improvement achievement was defined as an increase of at least 0.5 points from baseline to week 54. Adjusted rates are reported.
Time frame: Week 54
Absolute Change in Patient-Reported Use of Short-Acting Rescue Therapy
Adjusted mean values are all equal to zero.
Time frame: Baseline to Week 54
Proportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings
The adjusted mean proportion of weeks without a nighttime awakening from baseline through week 54 are reported. The proportion of weeks is expressed as a percentage.
Time frame: Baseline through Week 54
Absolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD)
The ADSD is a 6-item daily measure of asthma symptom severity that assesses three core categories of asthma symptoms: breathing symptoms, chest symptoms, and cough. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (no symptoms) to 10 (the worst symptoms imaginable). Adjusted means are reported.
Time frame: Baseline to Week 54
Percentage of Participants With Adverse Events
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline to Week 54
Percentage of Participants With Anti-Drug Antibodies (ADAs)
The prevalence of ADAs at baseline was defined as the proportion of the evaluable participant population in a study that is ADA positive at baseline.
Time frame: Baseline
Serum Concentration of Astegolimab (MSTT1041A)
Time frame: Weeks 26 and 54
Percentage of Participants With Treatment-Emergent ADAs
The incidence of ADAs at post-baseline timepoints was defined as the proportion of the study population found to have developed treatment-emergent ADAs.
Time frame: From baseline to the first appearance of ADAs at any point post-baseline (up to Week 54)
Adult participants with severe, uncontrolled asthma receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one additional controller medication.
| Milestone | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Started | 127 | 127 | 126 | 122 |
| Completed | 121 | 117 | 117 | 113 |
| Not completed | 6 | 10 | 9 | 9 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 1 |
| Withdrew: Principal investigator request | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 3 | 2 | 0 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 4 | 6 | 4 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 |
FEV1 measures how much air a person can exhale during the first second of a forced breath. Adjusted means are reported.
| Milliliters (mL) | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | 107 ± 47 | 130 ± 70 | 154 ± 93 | 172 ± 110 |
Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days.
| Weeks | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Time to First Asthma Exacerbation | NA (46.6 to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The AQLQ measures the functional problems (physical, emotional, social, and occupational) most troublesome to adults (17-70 years) with asthma. There are 32 questions in 4 domains - symptoms, activity limitation, emotional function, and environmental stimuli - scored on a 7 point scale, with 7= no impairment and 1= severely impaired. For this study, improvement achievement was defined as an increase of at least 0.5 points from baseline to week 54. Adjusted rates are reported.
| Percentage | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Week 54 - Responder | 55.3 | 64.8 | 61.3 | 68.9 |
| Week 54 - Non-responder | 44.7 | 35.2 | 38.7 | 31.1 |
Adjusted mean values are all equal to zero.
| Usage | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Absolute Change in Patient-Reported Use of Short-Acting Rescue Therapy | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
The adjusted mean proportion of weeks without a nighttime awakening from baseline through week 54 are reported. The proportion of weeks is expressed as a percentage.
| Percentage of weeks | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Proportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings | 0.4 (-0.7 to 1.5) | 0.4 (-0.7 to 1.5) | 0.3 (-0.7 to 1.3) | 0.3 (-0.7 to 1.3) |
The ADSD is a 6-item daily measure of asthma symptom severity that assesses three core categories of asthma symptoms: breathing symptoms, chest symptoms, and cough. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (no symptoms) to 10 (the worst symptoms imaginable). Adjusted means are reported.
| Scores on a scale | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Absolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD) | -1 (-2 to -1) | -2 (-2 to -1) | -1 (-2 to -1) | -1 (-2 to -1) |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Percentage of Participants With Adverse Events | 77.2 | 70.9 | 72.2 | 72.1 |
The prevalence of ADAs at baseline was defined as the proportion of the evaluable participant population in a study that is ADA positive at baseline.
| Percentage | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Percentage of Participants With Anti-Drug Antibodies (ADAs) | 5.6 | 0.8 | 1.6 | 1.7 |
| ug/mL | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|
| Week 26 pre-dose | 4.75 ± 123.3 | 16.9 ± 167.3 | 40.5 ± 161.2 |
| Week 54 | 4.47 ± 144.1 | 17.4 ± 155.4 | 38.7 ± 226.4 |
The incidence of ADAs at post-baseline timepoints was defined as the proportion of the study population found to have developed treatment-emergent ADAs.
| Percentage | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent ADAs | 7.1 | 9.6 | 8.9 | 3.3 |
Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Adjusted rates for the overall mITT population (all participants that received at least one dose of study drug) were estimated using Poisson regression and adjusted for blood eosinophil level at the first visit, the number of asthma exacerbations requiring systemic corticosteroids in the 12 months prior to study entry, the total daily ICS dose at the first visit, and geographic region, with patient time at risk used as an offset term.
| Number of asthma exacerbations per year | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| Reduction in Rate of Asthma Exacerbations | 0.74 | 0.47 | 0.58 | 0.42 |
Collected over Baseline to Week 54. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/127 (0%) | 8/127 (6.3%) | 76/127 (59.8%) |
| Astegolimab (MSTT1041A) 70mg | 0/127 (0%) | 14/127 (11%) | 65/127 (51.2%) |
| Astegolimab (MSTT1041A) 210mg | 1/126 (0.8%) | 9/126 (7.1%) | 75/126 (59.5%) |
| Astegolimab (MSTT1041A) 490mg | 1/122 (0.8%) | 6/122 (4.9%) | 68/122 (55.7%) |
| Event | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 2/127 | 2/127 | 4/126 | 1/122 |
| Atrial fibrillationCardiac disorders | 0/127 | 0/127 | 2/126 | 0/122 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/127 | 2/127 | 0/126 | 0/122 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/127 | 2/127 | 0/126 | 0/122 |
| CataractEye disorders | 0/127 | 0/127 | 0/126 | 1/122 |
| DeathGeneral disorders | 0/127 | 0/127 | 1/126 | 1/122 |
| CellulitisInfections and infestations | 0/127 | 0/127 | 0/126 | 1/122 |
| PneumoniaInfections and infestations | 1/127 | 1/127 | 0/126 | 1/122 |
| Vocal cord disorderRespiratory, thoracic and mediastinal disorders | 0/127 | 0/127 | 0/126 | 1/122 |
| Hypertensive crisisVascular disorders | 0/127 | 0/127 | 0/126 | 1/122 |
| Event | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 58/127 | 42/127 | 53/126 | 39/122 |
| NasopharyngitisInfections and infestations | 13/127 | 12/127 | 21/126 | 16/122 |
| HeadacheNervous system disorders | 6/127 | 8/127 | 6/126 | 14/122 |
| Upper respiratory tract infectionInfections and infestations | 12/127 | 9/127 | 8/126 | 6/122 |
| Injection site reactionGeneral disorders | 1/127 | 10/127 | 8/126 | 6/122 |
| InfluenzaInfections and infestations | 5/127 | 2/127 | 2/126 | 7/122 |
| RhinitisInfections and infestations | 7/127 | 7/127 | 3/126 | 2/122 |
| SinusitisInfections and infestations | 3/127 | 7/127 | 3/126 | 5/122 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/127 | 7/127 | 4/126 | 4/122 |
| Back painMusculoskeletal and connective tissue disorders | 7/127 | 5/127 | 5/126 | 4/122 |
| Age, Continuous(years) | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg | Total |
|---|---|---|---|---|---|
| Mean | 51.4 ± 12.2 | 52.4 ± 11.9 | 52.5 ± 12.0 | 51.4 ± 12.0 | 51.9 ± 12.0 |
| Sex: Female, Male(Participants) | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg | Total |
|---|---|---|---|---|---|
| Female | 82 | 81 | 90 | 79 | 332 |
| Male | 45 | 46 | 36 | 43 | 170 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 19 | 15 | 14 | 66 |
| Not Hispanic or Latino | 109 | 108 | 110 | 108 | 435 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Astegolimab (MSTT1041A) 70mg | Astegolimab (MSTT1041A) 210mg | Astegolimab (MSTT1041A) 490mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 5 | 8 | 4 | 22 |
| Asian | 6 | 4 | 4 | 9 | 23 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 9 | 6 | 6 | 29 |
| White | 107 | 105 | 108 | 102 | 422 |
| More than one race | 1 | 4 | 0 | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
Showing the first 100 of 138 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Apr 2019, 30 months.
Results were first posted in Dec 2022, 3 years 8 months after primary completion. A results delay was requested in Apr 2020.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 30 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Astegolimab